Champions Oncology, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2018, compared with fiscal 2017. Although the request refers to “2017 Q4,” this filing is an annual report for fiscal 2018, not a standalone quarterly filing.
Business context
Champions develops and sells TumorGraft-based oncology research services. Its Translational Oncology Solutions (TOS) business provides preclinical studies to pharmaceutical and biotechnology companies; Personalized Oncology Solutions (POS) supports personalized treatment planning. Management’s growth focus is TOS, TumorBank expansion, and development of humanized-immune-system “ImmunoGrafts.” POS is not a primary growth focus.
Financial performance and liquidity
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $20.241 million | $15.411 million |
| Cost of oncology solutions | $10.553 million | $9.703 million |
| Gross margin | 47.9% | 37.0% |
| Operating loss | $1.354 million | $6.809 million |
| Net loss | $1.476 million | $6.884 million |
| Net loss per share, basic and diluted | $0.13 | $0.64 |
| Cash used in operating activities | $1.226 million | $2.840 million |
| Cash used in investing activities | $1.226 million | $0.766 million |
TOS revenue was approximately $18.8 million, up 37.2%; POS revenue was approximately $1.5 million, down 15.4%. The filing attributes overall growth to more and larger TOS studies. Sales and marketing expense fell 21.2% to $2.570 million, and general and administrative expense fell 18.0% to $4.071 million; research and development rose 2.5% to $4.401 million.
At April 30, 2018, cash and cash equivalents were $856,000 (versus $3.295 million a year earlier), current assets were $5.060 million, and current liabilities were $7.453 million, yielding negative working capital of approximately $2.4 million. Total liabilities were $8.075 million and stockholders’ equity was approximately $3,000. The company reported an accumulated deficit of $70.8 million.
The company had no borrowings under its $1.5 million secured bank line at year-end; the line was due on demand, bore interest at prime plus 1.5%–2.0%, and had a stated maturity of October 29, 2018. A laboratory-equipment capital lease had $42,000 of remaining payments at year-end. The filing reports no off-balance-sheet debt. Management believed cash on hand and continued improvement in operating cash flows would fund operations through at least August 2019, while cautioning that additional financing might be required and could not be assured.
Changes, outlook, risks, and unusual items
- Revenue increased 31.3%, while operating expenses declined 2.8%; gross margin improved by 10.9 percentage points. Net loss narrowed substantially year over year.
- Cash declined by $2.439 million during FY2018. Property and equipment purchases were $1.229 million, primarily associated with laboratory investment and facilities.
- Management provided no numerical revenue, earnings, or cash-flow guidance. It identified continued TOS growth, larger studies, TumorBank expansion, and ImmunoGraft development as strategic priorities.
- Liquidity remains a central risk: the company has a long loss history, negative working capital, low cash, and substantial dependence on improved operating cash flow or access to capital. Management stated that failure to obtain needed capital could force curtailment or cessation of operations.
- Two customers represented 20.6% and 12.8% of FY2018 revenue; two customers represented 22.6% and 19.0% of year-end receivables. TOS studies may be canceled or changed when customers revise drug-development plans.
- Other key risks include competition, the platform’s lack of patent protection, potential FDA oversight of laboratory-developed tests, laboratory or mouse-colony disruption, limited patient reimbursement, and dilution from future equity issuance or outstanding options and warrants.
- The company recorded a one-time approximately $7.6 million reduction in deferred tax assets following U.S. tax-law changes, offset by a corresponding valuation-allowance reduction. It maintained a full valuation allowance on deferred tax assets and disclosed possible Section 382 limits on tax attributes.
- The company planned to adopt the new revenue-recognition standard on May 1, 2018, using the modified retrospective method. It expected no material financial-statement impact, but was still reviewing contracts, including certain co-clinical arrangements.
- The filing reports no material legal proceedings. The auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective.
Important facts for investors to verify
- Whether operating cash flow continues to improve enough to support management’s stated funding horizon, and whether the bank line was renewed or replaced after its October 2018 maturity.
- Whether the reported revenue growth and gross-margin improvement persist, particularly as TOS studies vary in size, timing, and cancellation risk.
- Customer concentration, receivables collection, and the conversion of unbilled receivables and deferred revenue into recognized revenue and cash.
- The final effects of adopting the revenue-recognition standard, especially on co-clinical contracts and timing of reported revenue.
- Capital needs and potential dilution, including the company’s outstanding options and warrants and any future financing terms.
- Regulatory developments affecting laboratory-developed tests, and progress in validating and commercializing ImmunoGrafts and TumorBank-derived data.